709 related articles for article (PubMed ID: 25139358)
1. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
[TBL] [Abstract][Full Text] [Related]
2. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
Front Immunol; 2022; 13():796349. PubMed ID: 35242129
[TBL] [Abstract][Full Text] [Related]
3. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.
Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Gress RE; Kanakry CG
J Clin Invest; 2019 Mar; 129(6):2357-2373. PubMed ID: 30913039
[TBL] [Abstract][Full Text] [Related]
5. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
Pillai AB; George TI; Dutt S; Strober S
Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
[TBL] [Abstract][Full Text] [Related]
6. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.
Kanakry CG; Ganguly S; Zahurak M; Bolaños-Meade J; Thoburn C; Perkins B; Fuchs EJ; Jones RJ; Hess AD; Luznik L
Sci Transl Med; 2013 Nov; 5(211):211ra157. PubMed ID: 24225944
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
[TBL] [Abstract][Full Text] [Related]
8. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
Fletcher RE; Nunes NS; Patterson MT; Vinod N; Khan SM; Mendu SK; Li X; de Paula Pohl A; Wachsmuth LP; Choo-Wosoba H; Eckhaus MA; Venzon DJ; Kanakry CG
Blood Adv; 2023 Apr; 7(7):1117-1129. PubMed ID: 36595377
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
11. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
12. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.
Yang J; Ramadan A; Reichenbach DK; Loschi M; Zhang J; Griesenauer B; Liu H; Hippen KL; Blazar BR; Paczesny S
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30694220
[TBL] [Abstract][Full Text] [Related]
13. A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.
Tawara I; Shlomchik WD; Jones A; Zou W; Nieves E; Liu C; Toubai T; Duran-Struuck R; Sun Y; Clouthier SG; Evers R; Lowler KP; Levy RB; Reddy P
J Immunol; 2010 Oct; 185(7):3866-72. PubMed ID: 20810991
[TBL] [Abstract][Full Text] [Related]
14. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
[TBL] [Abstract][Full Text] [Related]
17. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
[TBL] [Abstract][Full Text] [Related]
18. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
19. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
20. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
